Jung Youn Kim1, Ji Eun Park1, Youngheun Jo1, Woo Hyun Shim1, Soo Jung Nam2, Jeong Hoon Kim3, Roh-Eul Yoo4, Seung Hong Choi4, Ho Sung Kim1. 1. Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. 2. Deparment of Neurosurgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. 3. Deparment of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. 4. Department of Radiology, Seoul National University College of Medicine, Seoul, Korea.
Abstract
BACKGROUND: Pseudoprogression is a diagnostic challenge in early posttreatment glioblastoma. We therefore developed and validated a radiomics model using multiparametric MRI to differentiate pseudoprogression from early tumor progression in patients with glioblastoma. METHODS: The model was developed from the enlarging contrast-enhancing portions of 61 glioblastomas within 3 months after standard treatment with 6472 radiomic features being obtained from contrast-enhanced T1-weighted imaging, fluid-attenuated inversion recovery imaging, and apparent diffusion coefficient (ADC) and cerebral blood volume (CBV) maps. Imaging features were selected using a LASSO (least absolute shrinkage and selection operator) logistic regression model with 10-fold cross-validation. Diagnostic performance for pseudoprogression was compared with that for single parameters (mean and minimum ADC and mean and maximum CBV) and single imaging radiomics models using the area under the receiver operating characteristics curve (AUC). The model was validated with an external cohort (n = 34) imaged on a different scanner and internal prospective registry data (n = 23). RESULTS: Twelve significant radiomic features (3 from conventional, 2 from diffusion, and 7 from perfusion MRI) were selected for model construction. The multiparametric radiomics model (AUC, 0.90) showed significantly better performance than any single ADC or CBV parameter (AUC, 0.57-0.79, P < 0.05), and better than a single radiomics model using conventional MRI (AUC, 0.76, P = 0.012), ADC (AUC, 0.78, P = 0.014), or CBV (AUC, 0.80, P = 0.43). The multiparametric radiomics showed higher performance in the external validation (AUC, 0.85) and internal validation (AUC, 0.96) than any single approach, thus demonstrating robustness. CONCLUSIONS: Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improved diagnostic performance for identifying pseudoprogression and showed robustness in a multicenter setting.
BACKGROUND: Pseudoprogression is a diagnostic challenge in early posttreatment glioblastoma. We therefore developed and validated a radiomics model using multiparametric MRI to differentiate pseudoprogression from early tumor progression in patients with glioblastoma. METHODS: The model was developed from the enlarging contrast-enhancing portions of 61 glioblastomas within 3 months after standard treatment with 6472 radiomic features being obtained from contrast-enhanced T1-weighted imaging, fluid-attenuated inversion recovery imaging, and apparent diffusion coefficient (ADC) and cerebral blood volume (CBV) maps. Imaging features were selected using a LASSO (least absolute shrinkage and selection operator) logistic regression model with 10-fold cross-validation. Diagnostic performance for pseudoprogression was compared with that for single parameters (mean and minimum ADC and mean and maximum CBV) and single imaging radiomics models using the area under the receiver operating characteristics curve (AUC). The model was validated with an external cohort (n = 34) imaged on a different scanner and internal prospective registry data (n = 23). RESULTS: Twelve significant radiomic features (3 from conventional, 2 from diffusion, and 7 from perfusion MRI) were selected for model construction. The multiparametric radiomics model (AUC, 0.90) showed significantly better performance than any single ADC or CBV parameter (AUC, 0.57-0.79, P < 0.05), and better than a single radiomics model using conventional MRI (AUC, 0.76, P = 0.012), ADC (AUC, 0.78, P = 0.014), or CBV (AUC, 0.80, P = 0.43). The multiparametric radiomics showed higher performance in the external validation (AUC, 0.85) and internal validation (AUC, 0.96) than any single approach, thus demonstrating robustness. CONCLUSIONS: Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improved diagnostic performance for identifying pseudoprogression and showed robustness in a multicenter setting.
Authors: D-S Kong; S T Kim; E-H Kim; D H Lim; W S Kim; Y-L Suh; J-I Lee; K Park; J H Kim; D-H Nam Journal: AJNR Am J Neuroradiol Date: 2011-01-20 Impact factor: 3.825
Authors: Marco Nolden; Sascha Zelzer; Alexander Seitel; Diana Wald; Michael Müller; Alfred M Franz; Daniel Maleike; Markus Fangerau; Matthias Baumhauer; Lena Maier-Hein; Klaus H Maier-Hein; Hans-Peter Meinzer; Ivo Wolf Journal: Int J Comput Assist Radiol Surg Date: 2013-04-16 Impact factor: 2.924
Authors: Virendra Kumar; Yuhua Gu; Satrajit Basu; Anders Berglund; Steven A Eschrich; Matthew B Schabath; Kenneth Forster; Hugo J W L Aerts; Andre Dekker; David Fenstermacher; Dmitry B Goldgof; Lawrence O Hall; Philippe Lambin; Yoganand Balagurunathan; Robert A Gatenby; Robert J Gillies Journal: Magn Reson Imaging Date: 2012-08-13 Impact factor: 2.546
Authors: Sean D McGarry; Sarah L Hurrell; Amy L Kaczmarowski; Elizabeth J Cochran; Jennifer Connelly; Scott D Rand; Kathleen M Schmainda; Peter S LaViolette Journal: Tomography Date: 2016-09
Authors: Ji Eun Park; Donghyun Kim; Ho Sung Kim; Seo Young Park; Jung Youn Kim; Se Jin Cho; Jae Ho Shin; Jeong Hoon Kim Journal: Eur Radiol Date: 2019-07-26 Impact factor: 5.315